Compass Therapeutics, Inc.
CMPX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $13 | $16 | $13 | $13 |
| G&A Expenses | $3 | $5 | $5 | $4 |
| SG&A Expenses | $3 | $5 | $5 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $16 | $21 | $18 | $17 |
| Operating Income | -$16 | -$21 | -$18 | -$17 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $1 | $1 | $2 |
| Pre-Tax Income | -$14 | -$20 | -$17 | -$15 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$14 | -$20 | -$17 | -$15 |
| % Margin | – | – | – | – |
| EPS | -0.1 | -0.14 | -0.12 | -0.11 |
| % Growth | 28.6% | -16.7% | -9.1% | – |
| EPS Diluted | -0.1 | -0.14 | -0.12 | -0.11 |
| Weighted Avg Shares Out | 138 | 138 | 138 | 137 |
| Weighted Avg Shares Out Dil | 138 | 138 | 138 | 137 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $0 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$14 | -$21 | -$18 | -$16 |
| % Margin | – | – | – | – |